Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 7:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 207 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Sleepiness Clear all
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study of the Effect of Armodafinil Treatment in Healthy Subjects With Excessive Sleepiness Associated With Jet Lag Disorder

NCT00758498
View directory record Official record
Conditions
Excessive Sleepiness
Interventions
armodafinil, placebo
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years to 65 Years
Enrollment
427 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
4
States / cities
Atlanta, Georgia • Crestview, Kentucky • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2013 · Synced Jul 21, 2026, 7:06 AM EDT
Completed Phase 2 Interventional

A Safety and Effectiveness Study of a Single Dose of JNJ-17216498 in Patients With Narcolepsy

NCT00424931
View directory record Official record
Conditions
Narcolepsy
Interventions
JNJ-17216498, Modafinil
Drug
Lead sponsor
Alza Corporation, DE, USA
Industry
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
16
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 13 more
Source: ClinicalTrials.gov public record
Updated May 22, 2014 · Synced Jul 21, 2026, 7:06 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Biomarkers of Insufficient Sleep and Sleepiness

NCT03130803
View directory record Official record
Conditions
Sleep Deprivation, Insufficient Sleep Syndrome, Sleep Wake Disorders
Interventions
Insufficient Sleep
Behavioral
Lead sponsor
University of Colorado, Boulder
Other
Eligibility
18 Years to 35 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Boulder, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 29, 2020 · Synced Jul 21, 2026, 7:06 AM EDT
No Longer Available No phase listed Expanded access

Expanded Access Program to Provide Treatment With Pitolisant to Adult Patients in the U.S. With Excessive Daytime Sleepiness Associated With Narcolepsy With or Without Cataplexy

NCT03433131
View directory record Official record
Conditions
Narcolepsy Without Cataplexy, Narcolepsy With Cataplexy
Interventions
Pitolisant
Drug
Lead sponsor
Harmony Biosciences Management, Inc.
Industry
Eligibility
18 Years and older
U.S. locations
71
States / cities
Birmingham, Alabama • Cullman, Alabama • Phoenix, Arizona + 60 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2019 · Synced Jul 21, 2026, 7:06 AM EDT
Recruiting Phase 2 Interventional

A Study to Evaluate the Efficacy and Safety of E2086 in Adults With Narcolepsy

NCT07493265
View directory record Official record
Conditions
Narcolepsy
Interventions
E2086, Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
17
States / cities
Santa Ana, California • Brandon, Florida • Medley, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Jul 21, 2026, 7:06 AM EDT
Completed Phase 2 Interventional

An Open Label Study of NLS-2 (Mazindol Extended Release) in Subjects With Narcolepsy

NCT05055024
View directory record Official record
Conditions
Narcolepsy With Cataplexy, Narcolepsy, Narcolepsy Without Cataplexy
Interventions
Mazindol
Drug
Lead sponsor
NLS Pharmaceutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
22
States / cities
Birmingham, Alabama • Redwood City, California • San Diego, California + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2023 · Synced Jul 21, 2026, 7:06 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Advancing Understanding of Transportation Options

NCT04141891
View directory record Official record
Conditions
Diabetic Retinopathy, Macular Degeneration, Glaucoma, Retinitis Pigmentosa, Vision Disorders, Acute Coronary Syndrome, Implantable Defibrillator User, Congestive Heart Failure, Hypertrophic Obstructive Cardiomyopathy, Orthostatic Hypotension, Syncope, Presyncope, Narcolepsy, Dementia, Multiple Sclerosis, Parkinson Disease, Brain Injuries, Spinal Cord Injuries, Stroke, Vertigo, Dizziness, Seizures, Substance Use, Insulin Dependent Diabetes Mellitus, Arthritis, Foot--Abnormalities, Chronic Obstructive Pulmonary Disease, Obstructive Sleep Apnea, End Stage Renal Disease, Sleep Apnea, Insomnia, Restless Legs Syndrome
Interventions
Driving Decision Aid, Older Drivers Website
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
529 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
3
States / cities
La Jolla, California • Aurora, Colorado • Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 20, 2025 · Synced Jul 21, 2026, 7:06 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Language of Sleepiness

NCT04323254
View directory record Official record
Conditions
Sleep, Sleep Disorder, Sleepiness
Interventions
Not listed
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 89 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
2
States / cities
La Jolla, California • San Diego, California
Source: ClinicalTrials.gov public record
Updated Nov 4, 2020 · Synced Jul 21, 2026, 7:06 AM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy, Safety and Tolerability of ALKS 2680 in Adults With Narcolepsy Type 1 (Brilliance NT1 - 304)

NCT07540897
View directory record Official record
Conditions
Narcolepsy Type 1
Interventions
ALKS 2680 Dose 1, ALKS 2680 Dose 2, Placebo
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
10
States / cities
Miami, Florida • Winter Park, Florida • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Jul 21, 2026, 7:06 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Sleepiness and the Risk of Falling

NCT00383357
View directory record Official record
Conditions
Aging, Balance, Sleep
Interventions
zolpidem
Drug
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
18 Years to 85 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2004
U.S. locations
1
States / cities
Boulder, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 19, 2007 · Synced Jul 21, 2026, 7:06 AM EDT
Recruiting Phase 3 Interventional

Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol

NCT07484217
View directory record Official record
Conditions
Major Depressive Disorder With Excessive Daytime Sleepiness Symptoms
Interventions
Solriamfetol 150 MG, Placebo
Drug
Lead sponsor
Axsome Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
508 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
13
States / cities
Chino, California • Redlands, California • Walnut Creek, California + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Jul 21, 2026, 7:06 AM EDT
Recruiting Phase 2 Interventional

A Long-term Extension Study of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia

NCT07096674
View directory record Official record
Conditions
Narcolepsy Type 1, Narcolepsy Type 2, Idiopathic Hypersomnia
Interventions
ORX750
Drug
Lead sponsor
Centessa Pharmaceuticals (UK) Limited
Industry
Eligibility
18 Years to 65 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
19
States / cities
Auburn, Alabama • Santa Ana, California • Miami, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Jul 21, 2026, 7:06 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Study to Assess Drowsiness, Cognition, Fall Risk After Metaxalone 640 mg and Metaxalone 800 mg

NCT06348303
View directory record Official record
Conditions
Healthy Participants
Interventions
Metaxalone m640 mg oral tablet, Metaxalone 800 mg oral tablet
Drug
Lead sponsor
Primus Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 6, 2025 · Synced Jul 21, 2026, 7:06 AM EDT
Withdrawn Not applicable Interventional

Comparison of Modafinil and Methylphenidate in Treatment of Excessive Daytime Sleepiness in Patients With Parkinson's Disease

NCT00393562
View directory record Official record
Conditions
Parkinson's Disease
Interventions
modafinil, methylphenidate
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
50 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 25, 2015 · Synced Jul 21, 2026, 7:06 AM EDT
Recruiting Phase 2 Interventional

A Study of TAK-360 in Adults With Narcolepsy Type 1 (Narcolepsy With Cataplexy)

NCT07633301
View directory record Official record
Conditions
Narcolepsy Type 1
Interventions
TAK-360, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 70 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
3
States / cities
Redwood City, California • Miami, Florida • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 28, 2026 · Synced Jul 21, 2026, 7:06 AM EDT
Completed Phase 4 Interventional

A Study to Investigate the Effect of XYWAV on Sleepiness, Polysomnography, and Functional Outcomes in Participants With Idiopathic Hypersomnia or Narcolepsy

NCT05875974
View directory record Official record
Conditions
Idiopathic Hypersomnia, Narcolepsy
Interventions
JZP258 (XYWAV)
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
29
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Irvine, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2025 · Synced Jul 21, 2026, 7:06 AM EDT
Completed Phase 4 Interventional Results available

Study to Evaluate Armodafinil Treatment in Improving Prefrontal Cortical Activation and Working Memory Performance

NCT00711516
View directory record Official record
Conditions
Excessive Sleepiness
Interventions
Armodafinil, Placebo
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
9
States / cities
Burlingame, California • San Diego, California • Stanford, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2013 · Synced Jul 21, 2026, 7:06 AM EDT
Completed Phase 3 Interventional Results available

"Six-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in OSA"

NCT02348619
View directory record Official record
Conditions
Obstructive Sleep Apnea
Interventions
JZP-110
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
22
States / cities
Birmingham, Alabama • Oceanside, California • Orange, California + 18 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2019 · Synced Jul 21, 2026, 7:06 AM EDT
Completed Phase 3 Interventional Results available

A Multicenter Study of the Efficacy and Safety of JZP-258 in the Treatment of Idiopathic Hypersomnia (IH) With an Open-label Safety Extension

NCT03533114
View directory record Official record
Conditions
Idiopathic Hypersomnia
Interventions
JZP-258, Placebo Oral Solution
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
40
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 35 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2021 · Synced Jul 21, 2026, 7:06 AM EDT
Terminated Not applicable Interventional Results available

Transcranial Direct Current Stimulation Therapy for Sleepiness Related to Shift Work Disorder (tDCS-SWORD)

NCT03879044
View directory record Official record
Conditions
Shift-Work Sleep Disorder
Interventions
Transcranial Direct Current Stimulation
Device
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 24, 2021 · Synced Jul 21, 2026, 7:06 AM EDT
Recruiting Not applicable Interventional

Whole Food Plant-based Diet Effect on Obstructive Sleep Apnea

NCT06395181
View directory record Official record
Conditions
Obstructive Sleep Apnea, Daytime Sleepiness
Interventions
Whole Food Plant-Based Diet
Behavioral
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Jul 21, 2026, 7:06 AM EDT
Completed Phase 1 Interventional Results available

A Study of a Single Intravenous Infusion Dose of TAK-925 in Participants With Idiopathic Hypersomnia

NCT04091438
View directory record Official record
Conditions
Idiopathic Hypersomnia
Interventions
TAK-925, TAK-925 Placebo
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
20
States / cities
Alabaster, Alabama • Glendale, Arizona • Little Rock, Arkansas + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2023 · Synced Jul 21, 2026, 7:06 AM EDT
Completed No phase listed Observational

Improving the Assessment of Hypersomnolence

NCT02884505
View directory record Official record
Conditions
Disorders of Excessive Somnolence
Interventions
Pupillometry, Psychomotor Vigilance Task, Auditory Evoked Potential, Hypersomnia Severity Index
Device · Behavioral · Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 89 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 21, 2019 · Synced Jul 21, 2026, 7:06 AM EDT
Completed No phase listed Observational

A Patient-Centric, Prospective, Observational, Non-Interventional Switch Study of XYWAV in Narcolepsy

NCT04803786
View directory record Official record
Conditions
Narcolepsy
Interventions
Transition from Xyrem to Xywav
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jun 29, 2022 · Synced Jul 21, 2026, 7:06 AM EDT